Uterine CancerNCT06401265
Recalling the Treatment and Prognosis of Upper Tract Urothelial Cancer (UTUC)
An observational study of Uterine Cancer, run by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation at 1 site in Taiwan.
Trial summary
Among urothelial cancers, upper urinary tract urothelial cancers, including renal pelvis and ureteral cancers have a higher incidence rate in Taiwan than Western countries. In particular, the proportion of female patients is similar to that of males. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Uterine Cancer
- How many people
- 8,000 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Jan 2018to 5 Sep 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with upper urinary tract urothelial carcinoma
Who may be able to join
- Case study of upper urinary tract urothelial cancer surgery
Who cannot join
- Cases of surgery for non-upper urinary tract urothelial cancer
Trial locations and contacts
1 site in 1 country.
About this study
Among urothelial cancers, upper urinary tract urothelial cancers, including renal pelvis and ureteral cancers have a higher incidence rate in Taiwan than Western countries. In particular, the proportion of female patients is similar to that of males. This situation is significantly different from that in foreign countries. The cause is currently uncertain.In the past, the arsenic contamination of groundwater made blackfoot disease become common and malignant in areas. Now, the number of kidney dialysis patients in Taiwan is increasing; and according to statistics, there is a significantly higher incidence of urothelial cancer among kidney dialysis patients. This may be caused by the use of traditional Chinese medicine or other unknown reasons.
- Conditions
- Uterine Cancer
- Medical subject headings
- Uterine Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
It is a retrospective and questionnaire-based study.
Measured: Patients with urothelial carcinoma of the upper urinary tract from January 2008 to December 2019.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2024
- Study start1 Jan 2018
- Primary completion8 Feb 2018
- Study completion5 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Uterine CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 8,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06401265
- Sponsor's protocol ID
- 06-X34-105
- Status last verified
- Feb 2022
- First submitted
- 2 May 2024
- Last updated
- 6 May 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Recalling the Treatment and Prognosis of Upper Tract Urothelial Cancer (UTUC)
- ClinicalTrials.gov ID
- NCT06401265
- Acronym / sponsor ID
- 06-X34-105
- Conditions
- Uterine Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 8,000 participants (actual)
- Lead sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 8 Feb 2018 (actual)
- Study completion
- 5 Sep 2022 (actual)
- First posted
- 6 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Among urothelial cancers, upper urinary tract urothelial cancers, including renal pelvis and ureteral cancers have a higher incidence rate in Taiwan than Western countries. In particular, the proportion of female patients is similar to that of males. This situation is significantly different from that in foreign countries. The cause is currently uncertain.In the past, the arsenic contamination of groundwater made blackfoot disease become common and malignant in areas. Now, the number of kidney dialysis patients in Taiwan is increasing; and according to statistics, there is a significantly higher incidence of urothelial cancer among kidney dialysis patients. This may be caused by the use of traditional Chinese medicine or other unknown reasons.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with upper urinary tract urothelial carcinoma
Key inclusion criteria (1 listed)
- Case study of upper urinary tract urothelial cancer surgery
Key exclusion criteria (1 listed)
- Cases of surgery for non-upper urinary tract urothelial cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
It is a retrospective and questionnaire-based study.
Time frame: Patients with urothelial carcinoma of the upper urinary tract from January 2008 to December 2019.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2024.
Related trials for Uterine Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Active, not recruiting
Prospective Study of TVRFA Treatment for FIGO Type 3-5 Uterine Fibroids
Leiomyoma (Uterine Fibroids)
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 3
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Endometrial Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Uterine Cancer, run by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
It is a retrospective and questionnaire-based study. (time frame: Patients with urothelial carcinoma of the upper urinary tract from January 2008 to December 2019.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2024.